Good morning :)
$
₹
Harrow Health Inc

Harrow Health Inc

HROW

NASDAQ
Asset Logo

Harrow Health Inc

HROW

NASDAQ
$27.265.16% (-1.48)
$
₹
$27.265.16% (-1.48)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $1.0B the stock is ranked 2694

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

82.91
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.99
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-13.51%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 9 analysts reports

Buy
9 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+138.27%

Earnings Growth

-5.29%

Rev. Growth

+28.59%

See Detailed Forecast

Company Profile

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
39.15
39.15
1Y Return
53.63%
53.63%
Buy Reco %
83.33
83.33
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
28.82
28.82
1Y Return
33.86%
33.86%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
116.96
116.96
1Y Return
73.91%
73.91%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
21.50
21.50
1Y Return
15.17%
15.17%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
24.21
24.21
1Y Return
2.19%
2.19%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 138.27% growth, versus a trailing 3-year CAGR of 20.50%.

2026
Current$27.28Baseline
Analyst Target - 1 year
Target$65+138.27%

All values in $

202220232024202520262027$25.44$40.79$56.14Target+138.27%
2026
Current$27.28Baseline
Analyst Target - 1 year
Target$65+138.27%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 28.59% growth, versus a trailing 3-year CAGR of 45.39%.

2025
Current$272.30Baseline
Forecast for Dec 2026
High$355.02+30.38%
Average$350.14+28.59%
Low$341+25.23%

All values in $ Million

20212022202320242025202672.4788.59130.19199.61272.30Low+25.23%Average+28.59%High+30.38%
2025
Current$272.30Baseline
Forecast for Dec 2026
High$355.02+30.38%
Average$350.14+28.59%
Low$341+25.23%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.46Baseline
Forecast for Dec 2026
High$0.74+61.75%
Average$0.43-5.29%
Low$0.14-69.4%

All values in $

202120222023202420252026-0.05-0.12-0.390.010.46Low-69.4%Average-5.29%High+61.75%
2025
Current$0.46Baseline
Forecast for Dec 2026
High$0.74+61.75%
Average$0.43-5.29%
Low$0.14-69.4%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

71.6
1
89
6.6
44.2
-27.6
70.6
-17.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue34.5848.9349.2566.8347.8363.7471.6389.0944.2070.66
Net Income-13.56-6.47-4.226.77-17.784.991.026.62-27.60-17.27
Net Profit Margin-39.21%-13.22%-8.56%10.14%-37.17%7.83%1.42%7.43%-62.44%-24.44%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Harrow Health Inc -82.91-
Eli Lilly and Company39.1530.281.13
Johnson & Johnson28.827.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare HROW with any stock or ETF
Compare HROW with any stock or ETF
Comparing from
HROW
LLY
JNJ
Loading...

Frequently asked questions

  1. Harrow Health Inc (HROW) share price today is $27.26 as of October 17, 2026 at 1:30 AM IST. The stock touched a day high of $28.67 and a day low of $27.14.

  2. Harrow Health Inc stock trades on NASDAQ under the ticker symbol HROW.

  3. Harrow Health Inc's market capitalization is $1.02B as of October 17, 2026 at 1:30 AM IST.

  4. Harrow Health Inc's price-to-earnings (P/E) ratio is N/A as of October 18, 2026.

  5. Harrow Health Inc's price-to-book (P/B) ratio is 82.91 as of October 18, 2026.

  6. Yes, You can buy Harrow Health Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Harrow Health Inc shares in three steps: 1. Search Harrow Health Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Harrow Health Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Harrow Health Inc (HROW) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3667 shares at the current price of $27.26.

Loading...